Get the Stockscreener App
169.26
0.59%
0.99
After Hours:
168.80
-0.46
-0.27%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $169.26, with a volume of 2.01M.
It is up +0.59% in the last 24 hours and down -7.52% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$168.27
Open:
$169.84
24h Volume:
2.01M
Relative Volume:
0.91
Market Cap:
$262.50B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
50.83
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+0.21%
1M Performance:
-7.52%
6M Performance:
+82.10%
1Y Performance:
+129.72%
1-Day Range:
$168.33
$170.26
1-Week Range:
$164.06
$170.89
52-Week Range:
$71.49
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
169.26 | 260.97B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,196.03 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 624.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 453.92B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 322.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 296.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca earnings up next after pipeline setback rattles investors By Investing.com - Investing.com South Africa
AstraZeneca PLC (LSE:AZN) Q2 2026: Everything You Need To Know A - GuruFocus
AstraZeneca moves closer to EU asthma approval for Trixeo Aerosphere - Yahoo Finance UK
AstraZeneca (AZN) Secures EU Approval Recommendation for Breast Cancer Treatment - GuruFocus
AstraZeneca stock trades steadily as oncology and rare disease growth supports earnings - AD HOC NEWS
AZN|AstraZeneca PLC|Price:168.290|Chg%:-1.440 - TradingKey
Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.54 a shareEarnings Preview - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AstraZeneca stock trades steadily as oncology and cardiovascular growth supports long term earnings - Ad-hoc-news.de
AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says - Law360
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EU Okays AstraZeneca’s Etcamah As US Wait Continues - insights.citeline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance - GuruFocus
AstraZeneca stock holds firm on oncology focus as recent results underline growth momentum - Ad-hoc-news.de
Why AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Still Anchor UK Healthcare Stocks - Kalkine Media
Etcamah approval: AstraZeneca (NASDAQ: AZN) wins EU OK in HR+ breast cancer - Stock Titan
AstraZeneca's Etcamah combo approved for breast cancer treatment in EU - London South East
AstraZeneca PLC (AZN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Astrazeneca Secures EU Approval For Etcamah In ER-positive Breast Cancer - DirectorsTalk Interviews
European Commission Approves Next-Generation SERD for First-Line Breast Cancer Treatment - Kalkine Media
REGAstraZeneca PLCEtcamah approved in the EU for ER+ breast cancer - TradingView
Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer - AstraZeneca
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm - Business Wire
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock steadies as oncology and vaccines underpin earnings momentum - Ad-hoc-news.de
Jefferies says September lung data can offset AstraZeneca trial failure - Proactive financial news
London Deal Activity Keeps Healthcare Stocks In Focus As AstraZeneca (LSE:AZN) Sets The Tone - Kalkine Media
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Canada
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - The Manila Times
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
AstraZeneca stock trades steady as oncology and cardiovascular portfolio underpin growth - Ad-hoc-news.de
Earnings Preview: AstraZeneca to Report Financial Results on July 27 - 富途牛牛
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula - GuruFocus
AstraZeneca stock trades steady as oncology and vaccines underpin growth - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock holds as earnings and pipeline milestones support valuation - Ad-hoc-news.de
AstraZeneca stock trades steady as oncology revenue supports 2025 outlook - Ad-hoc-news.de
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
What Is Keeping AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock steadies as oncology growth supports guidance after latest quarterly update - Ad-hoc-news.de
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect - The National Law Review
AstraZeneca stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect - The National Law Review
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca stock trades steadily as oncology and rare disease growth underpin earnings - Ad-hoc-news.de
What Is Putting AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):